New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
CellTalk Blog
What is a Contract Research Organization (CRO), and How Do You Choose the Right One?
June 4, 2025
More infoPosters
Efficient tracking of electronic noise in BD LSR Fortessa without routine baseline checks
May 30, 2025
More infoCellTalk Blog
Optimizing T-Cell Engager (TCE) Development: Insights You Need for Clinical and Regulatory Success
May 27, 2025
More info